GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
In continuation of our letter dated February 14, 2023 on the Consolidated and Standalone Unaudited Financial Results for the quarter and nine months ended December 31, 2022, please find enclosed herewith a copy of Press Release being issued by the Company in this regard. GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Statement Of Deviation Or Variation Or Utilization Of Funds Raised Under Preferential Issue - Regulation 32(1) Of SEBI (LODR) Regulations, 2015 For The Quarter Ended December 31, 2022
In compliance with the Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find attached the Statement of Deviation or Variation or Utilization of funds raised through Preferential Issue by the Company for the quarter ended December 31, 2022, as reviewed by the Audit Committee. GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Board Meeting Outcome for Outcome Of Board Meeting Held On February 14, 2023
In compliance with the provisions of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at their meeting held today, February 14, 2023, has inter alia considered and approved the following: i. Un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2022. Copies of the following enclosed as Annexure- I Un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2022; Limited Review Report of the Statutory Auditors on aforesaid results. The meeting of Board commenced at 5.00 p.m. and concluded at 6.15 p.m. GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Results- Un-Audited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended December 31, 2022
In compliance with the provisions of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company, at their meeting held today, February 14, 2023 has inter alia considered and approved the following: i. Un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2022. Copies of the following enclosed as Annexure- I Un-audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2022; Limited Review Report of the Statutory Auditors on aforesaid results. The meeting of Board commenced at 5.00 p.m. and concluded at 6.15 p.m. GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Announcement under Regulation 30 (LODR)-Allotment
We hereby inform you that the Board of Directors of at their meeting held today i.e. February 11, 2023 has today allotted 7,50,000 equity shares of face value of Rs. 5/- each to Ms. Elizabeth Mathew. In terms of issue of Warrants, Ms. Elizabeth Mathew -non promoter has exercised the option of conversion of 7,50,000 Warrant into equity shares and the Company upon receipt of 75% of the balance money on said Warrants, has today allotted 7,50,000 equity shares of face value of Rs. 5/- each to Ms. Elizabeth Mathew. GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Board Meeting Intimation for Intimation Of Board Meeting To Approve The Un-Audited Financial Results For The Quarter And Nine Months Ended December 31, 2022.
GENESYS INTERNATIONAL CORPORATION LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2023 ,inter alia, to consider and approve Pursuant to the provisions under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable provisions, rules and regulations, if any, this is to inform you that a meeting of the Board of Directors of the Company will be held on Tuesday, February 14, 2023, to inter alia consider and approve the un-audited financial results (standalone and consolidated) for the quarter and nine months ended December 31, 2022 GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
The Compensation Committee at its meeting held on January 23, 2023, has approved the allotment of 46,726 equity shares of face value of Rs. 5/- each pursuant to the exercise of the Stock Options by the eligible employees of the company under the Genesys ESOP Scheme -2020. Consequently, post-allotment the paid-up capital of the company shall stand increased to Rs. 18,48,55,620/- divided into 3,69,71,124 equity shares of face value of Rs. 5/- each. These shares shall rank pari passu with the existing equity shares of the Company in all respects. GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
In compliance with Regulation 39 (3) of Securities and Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015 and as informed by the Registrar and Share Transfer Agent, intimation is hereby given regarding loss of share certificate(s) and issue of duplicate share certificate as per attachment. GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In Compliance with the Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we are enclosing herewith the certificate received from M/s. Bigshare Services Private Limited the Registrar and Share Transfer Agent of the Company for the quarter ended December 31, 2022. GENESYS INTERNATIONAL CORPORATION LTD. - 506109 - Closure of Trading Window
This is to inform you that as per the Company's Code of Conduct framed under the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in securities of the Company shall remain closed for all Designated Persons and their immediate relatives from January 01, 2023, till the expiry of 48 hours after the declaration of financial results of the Company for the quarter ended December 31, 2022.